6th DIA China Annual Meeting

During the last few years, an increasing number of new drug development programs in China are driven by Chinese domestic companies. These companies include both large pharmaceutical companies with integrated R&D capabilities or specialized, smaller biotech companies. The products under development include both small and large molecules. While some of these development efforts are for China market, a few programs are positioned towards a China led early clinical development followed by subsequent global or Asian development. What is the future direction of China-led development programs? What are the learning from such efforts? We have invited R&D heads of the domestic pharmaceutical companies, chief executives of the Chinese biotech companies, and senior executives of major CRO company to reflect on their progress and share their insights on Chinaled local and global development. This special session will be the only forum in this DIA China annual meeting dedicated to Chinese domestic companies. Senior executives from Yangzijiang, Hengrui, Zhejiang Beta Pharma, Hutchison MediPharma, and leading CRO company such as Wuxi AppTec will share the stage to have an open discussion on the global strategy of China new drug development.